Compare GSK plc (GSK) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Shell PLC — how do they compare? GSK plc trades at $52.85 (market cap $101.34B), while Shell PLC trades at $85 (market cap $228.96B). The key difference: Shell PLC is far larger — about 2.3× GSK plc's market cap, and Shell PLC pays the higher dividend (3.69%). Which is the better fit depends on your goals.
| GSK | SHEL | |
|---|---|---|
Market Cap | $101.34B | $228.96B |
Sector | Health | Energy |
52-Week High | $61.18 | $94.15 |
52-Week Low | $36.20 | $70.28 |
Enterprise Value | $121.95B | $281.49B |
Dividend Yield | 3.49% | 3.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Shell (SHEL) trades at $85.43, up 1.21% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows strong valuation metrics with a P/E of 13.18 and P/S of 0.93, supported by recent earnings beats and a 7.01% net income margin. Recent news highlights strategic moves including the ARC Resources acquisition and Venezuela gas field development, while cash flow trends indicate operational strength despite net outflows.
Outlook remains positive with a consensus price target of $122.20, reflecting 43% upside potential, driven by robust gas trading and refining margins. Key risks include Middle East production disruptions and volatile oil prices, but analyst sentiment is strongly bullish with 69% buy ratings. The dividend yield and debt reduction efforts provide additional shareholder value support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
